Heart Attack

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer...

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer...

Biostate AI’s Indian Subsidiary Bayosthiti Partners with Narayana Health to Build World’s Largest India-Specific Cardiac AI Dataset

Landmark 12,000-patient study addresses critical gap in global healthcare: South Asian populations face heart disease at younger ages but are...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens Specialty Pharmacy and Sterling...

Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the...

Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the...

Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit

DUBLIN and BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the...

Remedy Robotics Debuts Pioneering Endovascular Surgical Robotic System and Completes World’s First Fully Remote Neurointerventional Procedures

Groundbreaking remotely operable robotic system to transform intervention for stroke and cardiovascular disease, while radically expanding access to care for...

error: Content is protected !!